Ohm confirms the likelyhood of MDS to be treated by Leronlimab.

Ohm and others, please bring this to NPs attention, there is a good size market there, currently Geron and some others doing clinical trials using a different mechanism of action.

Quote:

---

I decided to go back and look at the MOAs of existing treatments. With one of them I saw it interacted with the cereblon ligase. From reading medical papers on cancer I knew that ligase was modulated by MIP1 (CCL3) and CCL3 binds to the CCR5 receptor.

I hunted down a medical paper that outlines how CCL3 interacts with myeloid cells. From that paper, Blocking the CCR5 receptor and downregulating CCL3 results in the mutated stem cells lower the production of abnormal red blood cells.

So there is a very good chance leronlimab could be a great treatment for MDS.

https://www.nature.com/articles/s41598-018-32978-y

---

Also https://www.ncbi.nlm.nih.gov/pubmed/23525654